1
|
Ter Brugge P, Moser SC, Bièche I, Kristel P, Ibadioune S, Eeckhoutte A, de Bruijn R, van der Burg E, Lutz C, Annunziato S, de Ruiter J, Masliah Planchon J, Vacher S, Courtois L, El-Botty R, Dahmani A, Montaudon E, Morisset L, Sourd L, Huguet L, Derrien H, Nemati F, Chateau-Joubert S, Larcher T, Salomon A, Decaudin D, Reyal F, Coussy F, Popova T, Wesseling J, Stern MH, Jonkers J, Marangoni E. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. Nat Commun 2023; 14:1958. [PMID: 37029129 PMCID: PMC10082194 DOI: 10.1038/s41467-023-37537-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 03/22/2023] [Indexed: 04/09/2023] Open
Abstract
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the in vivo response to platinum agents in 55 patient-derived xenografts (PDX) of TNBC to identify determinants of response. The HRD status, determined from whole genome sequencing, is highly predictive of platinum response. BRCA1 promoter methylation is not associated with response, in part due to residual BRCA1 gene expression and homologous recombination proficiency in different tumours showing mono-allelic methylation. Finally, in 2 cisplatin sensitive tumours we identify mutations in XRCC3 and ORC1 genes that are functionally validated in vitro. In conclusion, our results demonstrate that the genomic HRD is predictive of platinum response in a large cohort of TNBC PDX and identify alterations in XRCC3 and ORC1 genes driving cisplatin response.
Collapse
Affiliation(s)
- Petra Ter Brugge
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Sarah C Moser
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Ivan Bièche
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Petra Kristel
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Sabrina Ibadioune
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Alexandre Eeckhoutte
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Roebi de Bruijn
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Eline van der Burg
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Catrin Lutz
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Stefano Annunziato
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Julian de Ruiter
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Sophie Vacher
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Laura Courtois
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Rania El-Botty
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Ahmed Dahmani
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Elodie Montaudon
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Ludivine Morisset
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Laura Sourd
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Léa Huguet
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Heloise Derrien
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Fariba Nemati
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | | | | | - Anne Salomon
- Department of Pathology, Institut Curie, PSL University, 75005, Paris, France
| | - Didier Decaudin
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Fabien Reyal
- Department of Surgery, Institut Curie, PSL University, 75005, Paris, France
| | - Florence Coussy
- Department of Medical Oncology, Institut Curie, PSL University, 75005, Paris, France
| | - Tatiana Popova
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jelle Wesseling
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Marc-Henri Stern
- Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
- INSERM U830, Institut Curie, PSL University, 75005, Paris, France
- Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jos Jonkers
- Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands.
| | - Elisabetta Marangoni
- Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France.
| |
Collapse
|
5
|
Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. J Natl Cancer Inst 2016; 108:djw148. [PMID: 27381626 DOI: 10.1093/jnci/djw148] [Citation(s) in RCA: 138] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 05/12/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in patient-derived xenograft (PDX) models of BRCA1-mutated and BRCA1-methylated triple-negative breast cancer. METHODS A cohort of 75 mice carrying BRCA1-deficient breast PDX tumors was treated with cisplatin, melphalan, nimustine, or olaparib, and treatment sensitivity was determined. In tumors that acquired therapy resistance, BRCA1 expression was investigated using quantitative real-time polymerase chain reaction and immunoblotting. Next-generation sequencing, methylation-specific multiplex ligation-dependent probe amplification (MLPA) and Target Locus Amplification (TLA)-based sequencing were used to determine mechanisms of BRCA1 re-expression in therapy-resistant tumors. RESULTS BRCA1 protein was not detected in therapy-sensitive tumors but was found in 31 out of 42 resistant cases. Apart from previously described mechanisms involving BRCA1-intragenic deletions and loss of BRCA1 promoter hypermethylation, a novel resistance mechanism was identified in four out of seven BRCA1-methylated PDX tumors that re-expressed BRCA1 but retained BRCA1 promoter hypermethylation. In these tumors, we found de novo gene fusions that placed BRCA1 under the transcriptional control of a heterologous promoter, resulting in re-expression of BRCA1 and acquisition of therapy resistance. CONCLUSIONS In addition to previously described clinically relevant resistance mechanisms in BRCA1-deficient tumors, we describe a novel resistance mechanism in BRCA1-methylated PDX tumors involving de novo rearrangements at the BRCA1 locus, demonstrating that BRCA1-methylated breast cancers may acquire therapy resistance via both epigenetic and genetic mechanisms.
Collapse
Affiliation(s)
- Petra Ter Brugge
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Petra Kristel
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Eline van der Burg
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Ute Boon
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Michiel de Maaker
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Esther Lips
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Lennart Mulder
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Julian de Ruiter
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Catia Moutinho
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Heidrun Gevensleben
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Elisabetta Marangoni
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Ian Majewski
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Katarzyna Józwiak
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Wigard Kloosterman
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Markus van Roosmalen
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Karen Duran
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Frans Hogervorst
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Nick Turner
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Manel Esteller
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Edwin Cuppen
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Jelle Wesseling
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| | - Jos Jonkers
- Affiliations of authors: Division of Molecular Pathology and Cancer Genomics Centre Netherlands (PtB, PK, EvdB, UB, MdM, EL, LM, JdR, JW, JJ), Division of Molecular Carcinogenesis (IM), Department of Epidemiology and Biostatistics (KJ), and Family Cancer Clinic and Department of Pathology (FH), The Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain (CM, ME); The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK (HG, NT); Laboratory of Preclinical Investigation, Translational Research Department, Curie Institute, Paris, France (EM); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands (WK, MvR, KD, EC); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain (ME); Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain (ME)
| |
Collapse
|